wichy-shutterstock-com-1
Wichy / Shutterstock.com
29 October 2015EuropePhilip Webber

Are the Broad Institute’s CRISPR patents too broad?

The ability of the CRISPR/Cas9 system to make precisely targeted mutations in genes, including human genes, has taken the biotech industry by storm. It has been described by some as being the most important development in biology since the discovery of the structure of DNA by Watson and Crick in 1953.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
28 May 2026   A European court dismissed a challenge by a German generics manufacturer, confirming the validity of a patent covering a blood cancer combination therapy.
Europe
21 May 2026   The court has imposed a financial penalty after finding it continued promoting banned devices online despite an injunction covering five European countries.
Europe
18 May 2026   A high-profile Paris-based partner and four others join the firm, bringing experience across M&A, venture capital and life sciences-focused transactions.